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Abstract 
A computer method and software based on the in vitro dissolution of 
drug preparations has been elaborated for the estimation of bioequivalence 
using Microsoft Excel 2007, Visual Basic programming language. The 
method generates a „dissolution surface‖ from the parameters of time (X-
axis), from pH (Y-axis) and from the dissolved amount (A) in % of the drug. 
This dissolution surface allows the determination of the general dissolution 
curve of the test and reference preparations. By supposing that the absorption 
rate constant is known from the literature, the change of the amount of 
dissolved drug as the function of time can be determined. On the base of this 
function the maximum amount of the dissolved drug in the gastrointestinal 
tract and the AUC can be calculated and the test/reference ratio can be 
determined. In the case of linear pharmacokinetics these ratios are identical 
to the ratios of parameters that can be calculated in the circulation. By 
generating parameters between the allowed biological limits the dissolved 
drug – time curves of „volunteers‖ in the necessary number are created with 
the randomly generated „residence times‖ and their confidence intervals can 
be determined, i.e. on the base of dissolution curves bioequivalence can be 
estimated. 
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Introduction 
A drug preparation is regarded as a substitute – containing an active 
agent of the same quantity and quality defined by the pharmacopoeia – for 
other preparation (Test-Reference) as far as the statistic difference - (the 
confidence interval of T/R ratio of values measured in volunteers) of the 
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main pharmacokinetic parameters (Cmax, AUC) measured in tests on healthy 
volunteers - falls between certain limits [Grezal and Vereczkey, 2012]. 
The preparations besides their active agents (described above) differ 
in the ingredients of their vehicles making up the greatest majority of their 
mass. This difference may result in different solution of the preparations in 
the intestines, consequently the quantity of drug entering the circulatory 
system may differ more than allowed. 
 This risk can be reduced by the (in vitro) ―dissolution‖ test previously 
performed. The dissolution check/determination is carried out in solutions in 
which the preparations spend supposedly ―longer‖ time while passing 
through the gastrointestinal tract and so, based on this, we can form a picture 
about the dissolution properties of the different drug formulations. The joint 
evaluation (the statistic analysis used- F1 and F2 values) of mostly different 
dissolution curves of the preparations and pH values in the different (from 
neutral to acidic) media result in –many times – not quite well established 
values in terms of  dissolution ―comparability‖.  
 The simulation technique introduced under makes the decision 
regarding equivalence more reliable by processing the information from the 
dissolution tests. The method rests on the reference to the in vitro 
assessments of bioequivalence tests. 
 
Results 
 Representing dissolution in a three-dimension space (X-axis = time, 
Y-axis = pH values, Z-axis = amount of dissolved substance A in %) we are 
given a ―dissolution surface‖ between the dissolution points (Fig.1). By 
using this ―dissolution surface‖ the ―mean‖ dissolution curve of the 
preparation passing through the gastrointestinal tract is determined. 
 
Figure 1. 
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According to the structure of the gastrointestinal tract  the preparation 
passes through the oesophagus into the stomach. (This passage due to the 
shortness of time can be neglected). The pH value of the gastric juices is 
pH1, and in this range the preparation stays for t01 time. Then, the first phase 
of general dissolution curve will be the phase pH1 curve of the dissolution 
surface extending to t02 point, at the end of which the quantity of dissolved 
substance is the z1%. Then we identify the t11 point of time belonging to the 
z1% in the curve of the pH2 dissolution surface (this was already been 
dissolved in the previous process), then we place the dissolution phase from 
t11 to t12 to the part of the general curve having already been framed up. 
(Until t12 point of time z2% has been dissolved). In other words the section of 
pH2 dissolution curve is applied to the already devised general dissolution 
curve, which starts at dissolution % i.e. at (z1%) –at the t11 point of time - in 
the general curve and lasts until the t12 point of time. The preparation passes 
through pH3, pH4 media entering the duodenum which is supposed to be of 
pH5 value. The process in continued as written above through the media of 
pH6 and pH7 value until the end of the gastrointestinal tract (pH7). 
If the dissolving media applied in ―in vitro‖ dissolution tests are 
identical with the composition of the dissolving media of the gastrointestinal 
tract, the general dissolution curve of the gastrointestinal tract can be 
regarded as ―realistic‖. As far as the solvents used for dissolution do not 
meet this requirement, the simulation does not necessarily lead to correct 
results. 
 Volunteers presented different reactions as to the passage of the 
preparation through the gastrointestinal tract (duration in the intestines varies 
according to the sections of the gastrointestinal tract - dissolution spaces). 
This difference can be modelled in the simulation by using the general 
dissolution curve of the gastrointestinal tract in the following way. 
 It may more or less be predicted how long (minimum and maximum) 
time a preparation is staying (without meal) in each organ (e.g. in the 
stomach minimum 10 and maximum 30 minutes, but an arbitrary 
combination can be tested). Then, a random number is generated in this 
designated interval by a random function of even distribution and in this tz 
range, this value is regarded as the duration time of the preparation (The 
designated durations correspond to the t11-t12 intervals. Consequently, 
―generating‖ a new volunteer is carried out by the generation of the random 
number at each section of the general dissolution curve (within the 
prescribed limits of the given sections, which can also be zero). The duration 
times obtained from the series of numbers generated in this way represent an 
individual volunteer. By means of this method arbitrary number of 
volunteers - accidently differing from each other - can be ―generated‖ and in 
their gastrointestinal tracts varying quantities of active agent of different 
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distribution are dissolved under the limits of reality ensured at the adequate 
level of dissolution test. 
 The next step is the calculation of the quantity of active agent 
measurable in the gastrointestinal tract of the ―volunteers‖ generated like 
this. Once the ―general‖ dissolution curve has been known in a volunteer, the 
quantity of the active agent entering the gastrointestinal tract in short period 
of time (e.g. in case of the present software six seconds) can be calculated. 
These quantities are continuously calculated, then - by the analogy of 
repeated dosing of deferent quantities of active agent - this is added to the 
quantity having already been in the gastrointestinal tract and in the meantime 
the active agent - dissolved in the gastrointestinal tract in this way - is being 
absorbed into the circulatory system.  As the kinetics of referent preparations 
used in the bioequivalence tests is known, the absorption rate constant of the 
active agent absorbed from the gastrointestinal tract into the circulatory 
system can be determined. This absorption rate equals the absorption rate of 
active agent ―disappearing‖ from the gastrointestinal tract. (The accuracy of 
this constant in the simulation is highly robust, which by test calculations 
with different values or – directly – analytically can be appreciated. 
 Thus, the volume of active agent - entering the gastrointestinal tract 
(administration in every six second) by means of dissolution and 
disappearing at a known constant absorption rate from the gastrointestinal 
tract - can be described in the function of time (Fig. 2). 
 
Figure 2. 
The change of the amount of dissolved drug as the function of time 
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As, based on the function above, the dissolved substance volume for 
the test and referent preparations – the maximum of the time curve and the 
area under the curve – can be calculated, the test/referent ratio can be 
determined. Supposing linear kinetics (if kinetics is not linear, simulation 
cannot be applied) in case of the test/referent ratio Cmax and AUC measured 
in the circulatory system equals the ratios calculated in the gastrointestinal 
tract. Generating the necessary number of ―volunteers‖  confidence intervals 
per parameters can be calculated i.e. based on the dissolution curves 
bioequivalence can be simulated. 
 The reliability of the results obtained is determined by the adequate in 
vitro simulation of the dissolution in the gastrointestinal tract. The rate of 
dissolution – in case of preparation of great variability - is determined by the 
―variety‖ of the composition of the dissolving medium (greatly influencing 
the speed of dissolution) at the given site of the gastrointestinal tract. 
Furthermore, in case of a preparation sensitive to the change in  dissolution 
conditions,   the time distribution of dissolved substance may significantly be 
different even in case of  identical preparations (in the gastrointestinal tract  
of the volunteer the composition of the dissolving medium may change or 
the absorption time of a particular preparation in a given section – dissolving 
medium – may also be different and this may give rise to the case that the 
same preparation is not equivalent with itself). This uncontrollable random 
factor may be eliminated by the ―adequate‖ in vitro dissolution test, 
consequently a more reliable decision is obtained as to the bioequivalence of 
the preparations.  
 Naturally the model can further be ―refined‖ as the dissolution rate 
may change in different ways in the different preparations in the function of 
concentration (the volume of the dissolving medium), the different qualities 
of the gastrointestinal tract (peristaltic), the appropriate model of which in 
the dissolution test is the rotation speed of the mixer. 
 These additional factors – by the procedures described above – may 
be built in the model without any difficulty, although, the need of 
information (the measurements carried out under different conditions) of a 
simulation like this is well over the data need of the previous technique. In 
case of preparations of great variability, in the function of dissolution 
conditions, the costs of invested work - due to the increased reliability of 
decision - would certainly return. 
 As far as the dissolution processes of the gastrointestinal tract could 
be modelled ―very well‖, the simulation (due to its reliability) in case of 
preparations of great variability (where sometimes it takes place that - based 
on the bioequivalence test e preparation  is not equivalent even with itself 
either) would give more reliable results than  bioequivalence tests (by 
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ensuring the identity of the test circumstances of the two preparations by 
simulation – which in ―in vivo” conditions cannot be achieved). 
 The two risk factors of the present practice of bioequivalence tests 
(on the one hand, the different dissolution rates of the two preparations in the 
gastrointestinal tract may differ from the in vitro data and on the on the 
other, we cannot control – especially not equalize – the dissolution times in 
the different dissolution surfaces of the gastro- intestinal tracts of the 
volunteers) may distort the ―similarities‖ of the preparations in both 
directions. I.e. based on the bioequivalence tests in case of ―really 
equivalent‖ preparations we can conclude that in-equivalence is present and 
vice versa. 
 The recommended simulation would result in a more reliable 
evaluation of the ―similarity‖ and its costs – as compared to the 
bioequivalence tests – would be reduced by more than one order of 
magnitude. The table made up of two simulation calculations illustrates the 
risk factors of bioequivalence tests. 
 The simulation program used takes into account even the dissolution 
changes due to change in the volume of the dissolving medium and the 
difference in the rpm of mixer‘s fan. Measurement was carried out at a fixed 
volume and rpm. The differences due to the change in volume and rpm are 
fictitious as they are estimations based on chemical knowledge. (In ―actual‖ 
situation they are also to be measured). 
 The calculation was carried out in 25 volunteers in ten series (i.e. in 
250 cases for  each pH volume -in the hypostatised ranges – random number 
were generated for the duration time, the volume of the dissolved substance 
and rpm – discretely for the test and the referent dissolution curves). 
 For the dissolution curves and the referent of the volunteers the same 
random number was used in the first case. The confidence intervals 
calculated in this way are in the Table 1. 
 
Table 1. 
The simulated confidence intervals for test and reference pairs under same 
conditions 
Cases Amax AUC 
Lower Upper Lower Upper 
1 1.042 1.090 0.846 0.894 
2 1.033 1.086 0.813 0.872 
3 1.024 1.080 0.841 0.896 
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4 1.024 1.076 0.806 0.868 
5 1.002 1.058 0.837 0.895 
6 1.030 1.073 0.811 0.871 
7 1.041 1.084 0.833 0.882 
8 1.010 1.068 0.814 0.881 
9 1.051 1.092 0.859 0.912 
10 1.021 1.070 0.826 0.875 
 
In the second case randomly (for the previous simulation) generated 
series was used in the test in each volunteer, whereas new, random numbers 
were generated for the referent dissolution curves. The results are contained 
in Table 2. 
 
Table 2. 
The simulated confidence intervals for test and reference pairs under not 
same conditions 
Cases Amax AUC 
Lower Upper Lower Upper 
1 1.003 1.128 0.824 0.943 
2 0.952 1.109 0.807 0.913 
3 0.944 1.078 0.786 0.869 
4 0.995 1.117 0.804 0.892 
5 0.942 1.076 0.811 0.896 
6 1.020 1.156 0.848 0.960 
7 0.930 1.060 0.826 0.916 
8 0.967 1.112 0.846 0.952 
9 1.067 1.283 0.846 0.938 
10 1.017 1.188 0.841 0.944 
 
By comparing the tables it is evident  that under not same conditions 
the two preparations are ―steadily‖ equivalent, the confidence interval falls 
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between the ranges of 0.8-1.25 meaning acceptance [EMA 2010] whereas  
under the same conditions, in pairwise running non equivalent results are 
present, too. So the risk between the two treatments is due to the 
occasionally uncontrollable difference in physiological change and/or the 
passage through the gastrointestinal tract of the volunteer. 
Naturally by increasing the number of cases the length of confidence 
interval is decreasing, so the distribution centre of the test/referent ratio per 
volunteer can get close to the safety borders, consequently ratios calculated 
for many volunteers do not fall between the safety intervals.  
Finally it should be  emphasized that, based on the method, by means 
of the amount of substance dissolved and absorbed in the intestines and the 
time curve, the time – when maximal amount of substance (Tmax) is present 
in the gastrointestinal tract - can be estimated. This is by no means identical 
with the Cmax time found in plasma after absorption, but it supplies a good 
estimate if the speed of dissolution is different in case of the two 
preparations. The 6 seconds ―sampling‖ results in a more correct assessment 
than the in vivo 15-30-60 minute sampling. 
 
Conclusion 
The simulation technique described does not appreciate 
bioequivalence or difference on the basis of the substance volume having 
entered the blood but on the basis of the quantity of medicine dissolved in 
the gastrointestinal tract, which the bioequivalence tests are directed at. The 
method allows avoiding the greatest ―in vivo‖ problem of bioequivalence 
tests: the inevitable ―intra-individual variability‖ in the volunteers, which in 
case of the so called medicines of great variability is a fairly high number 
and may need an involvement of more than sixty volunteers [Tóthfalusi and 
Endrényi, 2012].   
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